CN102335362B - Traditional Chinese medicine for treating insulin resistance of type 2 diabetes - Google Patents
Traditional Chinese medicine for treating insulin resistance of type 2 diabetes Download PDFInfo
- Publication number
- CN102335362B CN102335362B CN 201110346174 CN201110346174A CN102335362B CN 102335362 B CN102335362 B CN 102335362B CN 201110346174 CN201110346174 CN 201110346174 CN 201110346174 A CN201110346174 A CN 201110346174A CN 102335362 B CN102335362 B CN 102335362B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- group
- type
- present
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine for treating insulin resistance of type 2 diabetes, and is used for solving the problem that the safe and efficient drugs for treating insulin resistance of type 2 diabetes are not available at present. The traditional Chinese medicine for treating insulin resistance of type 2 diabetes is prepared from the following components in parts by weight: 10-20 parts of American ginseng, 20-40 parts of coix seed and 10-20 parts of alisma. The traditional Chinese medicine has mild drug property and low toxic and side effect, and is used for treating insulin resistance of type 2 diabetes with the main characteristics, such as deficiency of spleen qi and interior accumulation of dampness and turbid. Compared with the similar traditional Chinese medicines, the traditional Chinese medicine has clear main active ingredients and definite disease treatment effect, and can obviously improve insulin resistance of type 2 diabetes.
Description
Technical field
The present invention relates to a kind of Chinese medicine for the treatment of the type 2 diabetes mellitus insulin resistant.
Background technology
Type 2 diabetes mellitus is take insulin resistant as main, with hypoinsulinism.Insulin resistant (insulin resistance, IR) refer to that body target organ or tissue are to Reduced susceptibility or the forfeiture of insulin biological effect, the ability that produces insulin in the type 2 diabetes mellitus patient body is not to completely lose, the interior insulin of the patient body that has even generation are too much, but the action effect of insulin is had a greatly reduced quality.Therefore, the insulin in the patient body may be in a kind of state of relative shortage.Up to the present, from the doctor trained in Western medicine angle, also do not treat the ideal medicament of insulin resistant.The euglycemic agent that use does not stimulate insulin secretion is advocated in the treatment of insulin resistant more, but this type of medicine can promote fat generation, and fat closely related with insulin resistant and diabetes, so doctor trained in Western medicine is inevitably treated contradiction to the treatment existence of type 2 diabetes mellitus insulin resistant.The Chinese medicine disease is paid attention to determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, by the integrally-regulated pathological state of improving human body, because Chinese medicine contains the number of chemical composition, can be for a plurality of target spots of disease, resist at the treatment diabetes insulin and have unique advantage aspect the Complex Diseases of this multifactor, many pathology target spot.Therefore, seek and major issue that the new Chinese medicine of the further investigation treatment type 2 diabetes mellitus insulin resistant person that becomes the work of Chinese medicine needs to be resolved hurrily.Yet still lacking at present safely and effectively, Chinese medicine can be used to intervene the diabetes insulin opposing.
Summary of the invention
The present invention is the problem that will solve the safe and effective medicine that still lacks at present treatment type 2 diabetes mellitus insulin resistant, and a kind of Chinese medicine for the treatment of the type 2 diabetes mellitus insulin resistant is provided.
The Chinese medicine that the present invention treats the type 2 diabetes mellitus insulin resistant is by weight by 10～20 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 20～40 parts Semen Coicis and 10～20 parts is made.
Radix Panacis Quinquefolii---function cures mainly: boosting qi and nourishing yin, clearing away heat and promoting production of body fluid.It is thanks to cloudy to be used for the deficiency of vital energy, interior-heat, and cough with asthma expectorant blood, deficiency-heat is tired tired, quenches one's thirst dryness of the mouth and throat.
Semen Coicis---function cures mainly: the spleen invigorating eliminating dampness by diuresis, and eliminating impediment antidiarrheal, row is dense in heat clearing away.Be used for edema, beriberi, dysuria, arthralgia chiefly caused by damp pathogen contracture, diarrhea due to hypofunction of the spleen, lung abscess, acute appendicitis.
Rhizoma Alismatis---function cures mainly: diuresis, clearing away damp-heat.Be used for dysuria, edema distension, the oliguria of having loose bowels, dizziness due to fluid-retention, the puckery pain of pyretic stranguria.
The type 2 diabetes mellitus insulin resistant determined curative effect as principal character is accumulate in treatment by Chinese herbs of the present invention in deficiency of spleen-QI, the turbid damp.Herbal nature of the present invention is gentle, and toxic and side effects is little, compares with similar Chinese medicine, and its main active is clear, and the treatment disease is clear and definite, can obviously improve the type 2 diabetes mellitus insulin resistant.The active component for the treatment of type 2 diabetes mellitus insulin resistant mainly is 20 (R) ginsenoside Rb1 in the Radix Panacis Quinquefolii of the present invention; The active component for the treatment of type 2 diabetes mellitus insulin resistant mainly is Semen Coicis polysaccharide A in the described Semen Coicis; The active component for the treatment of type 2 diabetes mellitus insulin resistant mainly is Alisol A-24-acetate in the described Rhizoma Alismatis.
Chinese medicine of the present invention can reduce fasting glucose (FBG) and the fasting insulin (FINS) of insulin resistance rat, rising insulin sensitivity index (ISI), the abnormal carbohydrate metabolism when improving insulin resistant.
The rising of serum triglycerides (TG) level and the generation of insulin resistant (IR) and type 2 diabetes mellitus are closely related, and long-term the competition with glucose of high TG enters in the cell, thereby have hindered the oxidation of glucose and utilization and cause blood sugar increasing.Free fatty (FFA) can suppress peripheral tissues to picked-up and the utilization of glucose, is one of main non-hormone substance that causes IR.Clinical research shows that the rising of plasma F FA can reduce whole body to the clearance rate of sugar, weakens simultaneously the inhibitory action that endogenous glucose is generated of insulin-mediated and rising blood glucose.Disorders of lipid metabolism is increasing of triglyceride (TG) and free fatty (FFA) particularly, is the initiating agent that causes insulin resistant (IR).Chinese medicine of the present invention can significantly reduce insulin resistance rat serum triglycerides and free fatty acid levels, but correcting lipid disorder improves the type 2 diabetes mellitus insulin resistant.
Phylaxin (Resistin) is a kind of peptide hormone by the adipose cell secretion of recently finding, and it can affect the glucose metabolism relevant with insulin action and lipid metabolism, because the function that has glucagon is named as phylaxin.Resistin can affect by acting on several approach such as Insulin receptor INSR and IRS, rise Suppressor of Cytokine Signaling-3 formation of insulin resistant.Tumor necrosis factor-alpha (TNF-α) plays a very important role in the pathogenesis of insulin resistant.TNF-α regulates insulin action by acting on insulin signaling pathway, suppresses the insulin signaling transduction.Leptin (Leptin) can promote steatolysis, suppress lipogenesis, Leptin can cause the insulin resistant of fatty tissue to the decomposition of fat itself, be that lipogenesis reduces, decomposes increase, produce a large amount of FFA and cause the insulin resistant of liver and muscle, so Leptin plays an important role in insulin resistant.Adiponectin (APN) is a kind of Adipocyte Factor of fatty tissue secretion, is the Adipocyte Factor that unique and body fat content are negative correlation in the body, is the important step of contact impaired glucose tolerance, insulin resistant and diabetic angiopathy.Chinese medicine of the present invention can significantly reduce Serum Resistin Levels, leptin, Tumor Necrosis Factor Alpha Levels, and the adiponectin that raises simultaneously can improve the type 2 diabetes mellitus insulin resistant by regulating above Adipocyte Factor level.
The specific embodiment
Technical solution of the present invention is not limited to the following cited specific embodiment, also comprises the combination in any between each specific embodiment.
The specific embodiment one: the Chinese medicine of present embodiment treatment type 2 diabetes mellitus insulin resistant is by weight by 10～20 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 20～40 parts Semen Coicis and 10～20 parts is made.
The Chinese medicine of present embodiment treatment type 2 diabetes mellitus insulin resistant can be made the oral formulations such as pill, tablet, powder, granule, drop pill, oral liquid according to existing conventional method.
The specific embodiment two: what present embodiment and the specific embodiment one were different is: the Chinese medicine for the treatment of type 2 diabetes mellitus insulin resistant is by weight by 10 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 20 parts Semen Coicis and 10 parts is made.Other is identical with the specific embodiment one.
The specific embodiment three: what present embodiment and the specific embodiment one were different is: the Chinese medicine for the treatment of type 2 diabetes mellitus insulin resistant is by weight by 20 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 40 parts Semen Coicis and 20 parts is made.Other is identical with the specific embodiment one.
The specific embodiment four: what present embodiment and the specific embodiment one were different is: the Chinese medicine for the treatment of type 2 diabetes mellitus insulin resistant is by weight by 15 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 40 parts Semen Coicis and 20 parts is made.Other is identical with the specific embodiment one.
The specific embodiment five: what present embodiment and the specific embodiment one were different is: the Chinese medicine for the treatment of type 2 diabetes mellitus insulin resistant is by weight by 20 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 25 parts Semen Coicis and 15 parts is made.Other is identical with the specific embodiment one.
The specific embodiment six: what present embodiment and the specific embodiment one were different is: the Chinese medicine for the treatment of type 2 diabetes mellitus insulin resistant is by weight by 10 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 30 parts Semen Coicis and 20 parts is made.Other is identical with the specific embodiment one.
The specific embodiment seven: the Chinese medicine of present embodiment treatment type 2 diabetes mellitus insulin resistant is by weight by 15 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 30 parts Semen Coicis and 15 parts is made.
The Chinese medicine of present embodiment treatment type 2 diabetes mellitus insulin resistant can prepare by the following method: get by weight the Radix Panacis Quinquefolii of 15g, the Semen Coicis of 30g and the Rhizoma Alismatis of 15g, the 3h that is soaked in water, then decocting 1h, taking liquid, decocting 1h again, taking liquid, merge medicinal liquid, be concentrated into 50mL, and get final product.
Experiment one: the Chinese medicine of present embodiment treatment type 2 diabetes mellitus insulin resistant is on glycometabolic impact
(1) preparation of type 2 diabetes mellitus Rat model of insulin-resistant
After 70 SD male rat adaptabilities fed for 1 week, be divided at random modeling group (60) and blank group (10), blank group feed normal diet, modeling group feed high lipid food (being made by 12% Adeps Sus domestica, 48% normal feedstuff, 15% sugar, 10% Semen arachidis hypogaeae, 10% egg yolk, 5% salt and 0.03% Fel Sus domestica salt by the quality percentage composition).Feed therebetween (the 8th week), the modeling group is injected 0.25% STZ solution (being dissolved in citric acid solution) by 25mg/Kg BW disposable celiac; The isopyknic citrate buffer of blank group lumbar injection.After 10 weeks, detect each Mus fasting glucose and fasting insulin level, calculate insulin sensitivity index (ISI).
(2) grouping and administration
Take insulin sensitivity index as screening index, screening modeling success rat is 54 in the modeling group, is divided at random the Chinese medicine high dose group (13) of present embodiment, Chinese medicine low dose group (13), rosiglitazone group (14) and the model group (14) of present embodiment.The Chinese medicine high dose group of present embodiment is pressed crude drug amount 10.8g/kg dosage gastric infusion; The Chinese medicine low dose group of present embodiment is pressed crude drug amount 5.4g/kg dosage gastric infusion; The rosiglitazone group is by 0.4mg/kg dosage gastric infusion (the rosiglitazone batch number is 0409002); Blank group and model group gavage the normal saline 10mL/kg of equal volume every day.
(3) observation index
Rat general status observation: the situations such as food ration, body weight, outward appearance and behavior variation of observing rat.Detect the serum insulin level.Use blood glucose meter and detect fasting glucose (FBG); Adopt radioactive immunoassay to measure serum insulin (FINS); Calculate simultaneously Insulin Sensitivity Index ISI=ln[1/ (FBG * FINS)].
Data SPSS software processes, the data of normal distribution with
Expression, the data of nonnormal distribution is carried out statistical analysis after all taking from right lognormal.
(4) experimental result
The observation of rat general status: before the modeling, each is organized, and activities in rats agility, fur are bright and clean, food ration, amount of drinking water, urine amount are all normal.Except the blank group, all the other rat aggregate performances are lethargy, bradykinesia, hair is withered and yellow unglazed after the modeling, and food ration, amount of drinking water and urine amount increase.
The Chinese medicine of present embodiment sees Table 1 to the impact of rat fasting blood-glucose (FBG), fasting insulin (FINS), insulin sensitivity index (ISI).
The Chinese medicine of table 1 present embodiment is on the impact of rat FBG, FINS and ISI
Annotate: 1. compare with the blank group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
Table 1 result shows, compares with the blank group, and model group rat FBG, FINS level raise, and ISI descends, and significant difference (P＜0.01) is arranged, and illustrates that insulin resistant model copies successfully.Compare with model group, each administration group rat FBG, FINS descend (P＜0.01), and ISI raises (P＜0.05) to some extent simultaneously, and difference has statistical significance.The result shows that the Chinese medicine of present embodiment can reduce FBG and the FINS of insulin resistance rat, rising ISI, the abnormal carbohydrate metabolism when improving insulin resistant.
Experiment two: the Chinese medicine of present embodiment treatment type 2 diabetes mellitus insulin resistant is on lipometabolic impact
(1) preparation of type 2 diabetes mellitus Rat model of insulin-resistant
After 70 SD male rat adaptabilities fed for 1 week, be divided at random modeling group (60) and blank group (10), blank group feed normal diet, modeling group feed high lipid food (being made by 12% Adeps Sus domestica, 48% normal feedstuff, 15% sugar, 10% Semen arachidis hypogaeae, 10% egg yolk, 5% salt and 0.03% Fel Sus domestica salt by the quality percentage composition).Feed therebetween (the 8th week), the modeling group is injected 0.25% STZ solution (being dissolved in citric acid solution) by 25mg/Kg BW disposable celiac; The isopyknic citrate buffer of blank group lumbar injection.After 10 weeks, detect each Mus fasting glucose and fasting insulin level, calculate insulin sensitivity index (ISI).
(2) grouping and administration
Take insulin sensitivity index as screening index, screening modeling success rat is 54 in the modeling group, is divided at random the Chinese medicine high dose group (13) of present embodiment, Chinese medicine low dose group (13), rosiglitazone group (14) and the model group (14) of present embodiment.The Chinese medicine high dose group of present embodiment is pressed crude drug amount 10.8g/kg dosage gastric infusion; The Chinese medicine low dose group of present embodiment is pressed crude drug amount 5.4g/kg dosage gastric infusion; The rosiglitazone group is by 0.4mg/kg dosage gastric infusion (the rosiglitazone batch number is 0409002); Blank group and model group gavage the normal saline 10mL/kg of equal volume every day.
(3) concentration of detection Triglycerides in Serum (TG), T-CHOL (TC) and these three kinds of materials of free fatty (FFA).
(4) experimental result
The Chinese medicine of table 2 present embodiment is on the impact of rat blood serum T-CHOL, triglyceride
| Grouping | n | TG(mmol/L) | TC(mmol/L) |
| Blank group | 10 | 0.69±0.21 | 1.78±0.14 |
| The Chinese medicine high dose group of present embodiment | 13 | 1.04±0.41 ★ | 1.88±0.52 ★★ |
| The Chinese medicine low dose group of present embodiment | 13 | 1.34±0.22 ★★ | 2.04±0.28 ★ |
| The rosiglitazone group | 14 | 1.25±0.30 ★★ | 1.96±0.46 ★★ |
| Model group | 14 | 2.15±0.19 ▲▲ | 3.36±0.32 ▲▲ |
Annotate: 1. compare with the blank group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
The Chinese medicine of table 3 present embodiment is to rat blood serum free-fat effect of acid
| Grouping | n | FFA(μmol/L) |
| Blank group | 10 | 656.2±89.7 |
| Model group | 14 | 1309.8±93.7 ▲▲ |
| The rosiglitazone group | 14 | 839.9±78.1 ★★ |
| The Chinese medicine high dose group of present embodiment | 13 | 861.6±75.8 ★★ |
| The Chinese medicine low dose group of present embodiment | 13 | 906.7±64.2 ★★ |
Annotate: 1. compare with the blank group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
Table 2 and table 3 result show, compare model group rat blood serum T-CHOL (TC), triglyceride (TG) level rising (P＜0.01) with the blank group; Compare each administration group Serum TC, TG level decline (P＜0.01) with model group.Table 3 result shows, compares model group rat blood serum free fatty (FFA) level rising (P＜0.01) with the blank group; Compare each administration group rat blood serum FFA level decline (P＜0.01) with model group.Above experimental result shows that the Chinese medicine of present embodiment can obviously reduce serum TC, TG and the FFA level of insulin resistance rat, the hyperlipidemia state when improving insulin resistant.
Experiment three: on the impact of Adipocyte Factor
(1) preparation of type 2 diabetes mellitus Rat model of insulin-resistant
After 70 SD male rat adaptabilities fed for 1 week, be divided at random modeling group (60) and blank group (10), blank group feed normal diet, modeling group feed high lipid food (being made by 12% Adeps Sus domestica, 48% normal feedstuff, 15% sugar, 10% Semen arachidis hypogaeae, 10% egg yolk, 5% salt and 0.03% Fel Sus domestica salt by the quality percentage composition).Feed therebetween (the 8th week), the modeling group is injected 0.25% STZ solution (being dissolved in citric acid solution) by 25mg/Kg BW disposable celiac; The isopyknic citrate buffer of blank group lumbar injection.After 10 weeks, detect each Mus fasting glucose and fasting insulin level, calculate insulin sensitivity index (ISI).
(2) grouping and administration
Take insulin sensitivity index as screening index, screening modeling success rat is 54 in the modeling group, is divided at random the Chinese medicine high dose group (13) of present embodiment, Chinese medicine low dose group (13), rosiglitazone group (14) and the model group (14) of present embodiment.The Chinese medicine high dose group of present embodiment is pressed crude drug amount 10.8g/kg dosage gastric infusion; The Chinese medicine low dose group of present embodiment is pressed crude drug amount 5.4g/kg dosage gastric infusion; The rosiglitazone group is by 0.4mg/kg dosage gastric infusion (the rosiglitazone batch number is 0409002); Blank group and model group gavage the normal saline 10mL/kg of equal volume every day.
(3) concentration of detection Serum Resistin Levels (Resistin), fat element (APN), Serum Leptin Levels (Leptin) and tumor necrosis factor-alpha (TNF-α).
(4) experimental result
The Chinese medicine of table 4 present embodiment is on the impact of rat blood serum Resistin, APN
| Grouping | n | Resistin(ng/mL) | APN(ng/mL) |
| Blank group | 10 | 13.74±3.05 | 4.31±0.68 |
| The Chinese medicine high dose group of present embodiment | 13 | 15.04±2.73 ★★ | 4.22±0.58 ★★ |
| The Chinese medicine low dose group of present embodiment | 13 | 15.86±2.19 ★ | 3.51±0.63 ★ |
| The rosiglitazone group | 14 | 19.47±3.24 | 3.98±0.51 ★★ |
| Model group | 14 | 19.65±3.11 ▲▲ | 2.53±0.62 ▲▲ |
Annotate: 1. compare with the blank group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
Table 4 result shows, compares model group rat blood serum phylaxin (Resistin) level rising (P＜0.01) with the blank group; With model group relatively, star-spangled banner pool core group rat blood serum Resistin level descends, high dose group P＜0.01 wherein, low dose group P＜0.05.Compare model group rat blood serum adiponectin (APN) level decline (P＜0.01) with the blank group; With model group relatively, the Chinese drug-treated group rat blood serum APN level of present embodiment raises, high dose group P＜0.01 wherein, low dose group P＜0.05.
The Chinese medicine of table 5 present embodiment is on the impact of rat blood serum Leptin and TNF-α
| Grouping | n | Leptin(ng/mL) | TNF-a(ng/mL) |
| Blank group | 10 | 2.548±0.523 | 1.873±0.194 |
| The Chinese medicine high dose group of present embodiment | 13 | 4.013±0.657 ★★ | 1.928±0.207 ★★ |
| The Chinese medicine low dose group of present embodiment | 13 | 4.563±0.692 ★★ | 2.197±0.223 ★ |
| The rosiglitazone group | 14 | 5.018±0.783 ★ | 2.054±0.215 ★★ |
| Model group | 14 | 5.906±0.628 ▲▲ | 2.549±0.201 ▲▲ |
Annotate: 1. compare with the blank group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
Table 5 result shows, compares model group serum leptin (Leptin) level rising (P＜0.01) with the blank group; Compare the Chinese medicine high and low dose group rat blood serum Leptin level decline (P＜0.01) of present embodiment with model group.Compare model group rat blood serum tumor necrosis factor-alpha (TNF-α) level rising (P＜0.01) with the blank group; With model group relatively, the Chinese drug-treated group rat blood serum TNF-a level of present embodiment descends, high dose group P＜0.01 wherein, low dose group P＜0.05.
The Chinese medicine of present embodiment can significantly reduce Serum Resistin Levels, leptin, Tumor Necrosis Factor Alpha Levels, and the adiponectin that raises simultaneously can improve the type 2 diabetes mellitus insulin resistant by regulating above Adipocyte Factor level.
The specific embodiment eight: the Chinese medicine of present embodiment treatment type 2 diabetes mellitus insulin resistant is by weight by 20 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 30 parts Semen Coicis and 10 parts is made.
The Chinese medicine of present embodiment treatment type 2 diabetes mellitus insulin resistant can prepare by the following method: get by weight the Radix Panacis Quinquefolii of 20g, the Semen Coicis of 30g and the Rhizoma Alismatis of 10g, the 3h that is soaked in water, then decocting 1h, taking liquid, decocting 1h again, taking liquid, merge medicinal liquid, be concentrated into 50mL, and get final product.
Experiment one: the Chinese medicine of present embodiment treatment type 2 diabetes mellitus insulin resistant is on glycometabolic impact
(1) preparation of type 2 diabetes mellitus Rat model of insulin-resistant
After 70 SD male rat adaptabilities fed for 1 week, be divided at random modeling group (60) and blank group (10), blank group feed normal diet, modeling group feed high lipid food (being made by 12% Adeps Sus domestica, 48% normal feedstuff, 15% sugar, 10% Semen arachidis hypogaeae, 10% egg yolk, 5% salt and 0.03% Fel Sus domestica salt by the quality percentage composition).Feed therebetween (the 8th week), the modeling group is injected 0.25% STZ solution (being dissolved in citric acid solution) by 25mg/Kg BW disposable celiac; The isopyknic citrate buffer of blank group lumbar injection.After 10 weeks, detect each Mus fasting glucose and fasting insulin level, calculate insulin sensitivity index (ISI).
(2) grouping and administration
Take insulin sensitivity index as screening index, screening modeling success rat is 54 in the modeling group, is divided at random the Chinese medicine high dose group (13) of present embodiment, Chinese medicine low dose group (13), rosiglitazone group (14) and the model group (14) of present embodiment.The Chinese medicine high dose group of present embodiment is pressed crude drug amount 10.8g/kg dosage gastric infusion; The Chinese medicine low dose group of present embodiment is pressed crude drug amount 5.4g/kg dosage gastric infusion; The rosiglitazone group is by 0.4mg/kg dosage gastric infusion (the rosiglitazone batch number is 0409002); Blank group and model group gavage the normal saline 10mL/kg of equal volume every day.
(3) observation index
Rat general status observation: the situations such as food ration, body weight, outward appearance and behavior variation of observing rat.Detect the serum insulin level.Use blood glucose meter and detect fasting glucose (FBG); Adopt radioactive immunoassay to measure serum insulin (FINS); Calculate simultaneously Insulin Sensitivity Index ISI=ln[1/ (FBG * FINS)].
Data SPSS software processes, the data of normal distribution with
Expression, the data of nonnormal distribution is carried out statistical analysis after all taking from right lognormal.
(4) experimental result
The observation of rat general status: before the modeling, each is organized, and activities in rats agility, fur are bright and clean, food ration, amount of drinking water, urine amount are all normal.Except the blank group, all the other rat aggregate performances are lethargy, bradykinesia, hair is withered and yellow unglazed after the modeling, and food ration, amount of drinking water and urine amount increase.
The Chinese medicine of present embodiment sees Table 1 to the impact of rat fasting blood-glucose (FBG), fasting insulin (FINS), insulin sensitivity index (ISI).
The Chinese medicine of table 1 present embodiment is on the impact of rat FBG, FINS and ISI
Annotate: 1. compare with the blank group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
Table 1 result shows, compares with the blank group, and model group rat FBG, FINS level raise, and ISI descends, and significant difference (P＜0.01) is arranged, and illustrates that insulin resistant model copies successfully.Compare with model group, each administration group rat FBG, FINS descend (P＜0.01), and ISI raises (P＜0.05) to some extent simultaneously, and difference has statistical significance.The result shows that the Chinese medicine of present embodiment can reduce FBG and the FINS of insulin resistance rat, rising ISI, the abnormal carbohydrate metabolism when improving insulin resistant.
Experiment two: the Chinese medicine of present embodiment treatment type 2 diabetes mellitus insulin resistant is on lipometabolic impact
(1) preparation of type 2 diabetes mellitus Rat model of insulin-resistant
After 70 SD male rat adaptabilities fed for 1 week, be divided at random modeling group (60) and blank group (10), blank group feed normal diet, modeling group feed high lipid food (being made by 12% Adeps Sus domestica, 48% normal feedstuff, 15% sugar, 10% Semen arachidis hypogaeae, 10% egg yolk, 5% salt and 0.03% Fel Sus domestica salt by the quality percentage composition).Feed therebetween (the 8th week), the modeling group is injected 0.25% STZ solution (being dissolved in citric acid solution) by 25mg/Kg BW disposable celiac; The isopyknic citrate buffer of blank group lumbar injection.After 10 weeks, detect each Mus fasting glucose and fasting insulin level, calculate insulin sensitivity index (ISI).
(2) grouping and administration
Take insulin sensitivity index as screening index, screening modeling success rat is 54 in the modeling group, is divided at random the Chinese medicine high dose group (13) of present embodiment, Chinese medicine low dose group (13), rosiglitazone group (14) and the model group (14) of present embodiment.The Chinese medicine high dose group of present embodiment is pressed crude drug amount 10.8g/kg dosage gastric infusion; The Chinese medicine low dose group of present embodiment is pressed crude drug amount 5.4g/kg dosage gastric infusion; The rosiglitazone group is by 0.4mg/kg dosage gastric infusion (the rosiglitazone batch number is 0409002); Blank group and model group gavage the normal saline 10mL/kg of equal volume every day.
(3) concentration of detection Triglycerides in Serum (TG), T-CHOL (TC) and these three kinds of materials of free fatty (FFA).
(4) experimental result
The Chinese medicine of table 2 present embodiment is on the impact of rat blood serum T-CHOL, triglyceride
| Grouping | n | TG(mmol/L) | TC(mmol/L) |
| Blank group | 10 | 0.63±0.21 | 1.78±0.23 |
| The Chinese medicine high dose group of present embodiment | 13 | 1.01±0.51 ★ | 1.79±0.45 ★★ |
| The Chinese medicine low dose group of present embodiment | 13 | 1.33±0.18 ★★ | 2.04±0.25 ★ |
| The rosiglitazone group | 14 | 1.18±0.30 ★★ | 1.96±0.56 ★★ |
| Model group | 14 | 2.05±0.15 ▲▲ | 3.33±0.29 ▲▲ |
Annotate: 1. compare with the blank group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
The Chinese medicine of table 3 present embodiment is to rat blood serum free-fat effect of acid
| Grouping | n | FFA(μmol/L) |
| Blank group | 10 | 653.7±88.1 |
| Model group | 14 | 1279.9±95.4 ▲▲ |
| The rosiglitazone group | 14 | 834.9±79.4 ★★ |
| The Chinese medicine high dose group of present embodiment | 13 | 854.4±75.1 ★★ |
| The Chinese medicine low dose group of present embodiment | 13 | 900.2±65.2 ★★ |
Annotate: 1. compare with the blank group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
Table 2 and table 3 result show, compare model group rat blood serum T-CHOL (TC), triglyceride (TG) level rising (P＜0.01) with the blank group; Compare each administration group Serum TC, TG level decline (P＜0.01) with model group.Table 3 result shows, compares model group rat blood serum free fatty (FFA) level rising (P＜0.01) with the blank group; Compare each administration group rat blood serum FFA level decline (P＜0.01) with model group.Above experimental result shows that the Chinese medicine of present embodiment can obviously reduce serum TC, TG and the FFA level of insulin resistance rat, the hyperlipidemia state when improving insulin resistant.
Experiment three: on the impact of Adipocyte Factor
(1) preparation of type 2 diabetes mellitus Rat model of insulin-resistant
After 70 SD male rat adaptabilities fed for 1 week, be divided at random modeling group (60) and blank group (10), blank group feed normal diet, modeling group feed high lipid food (being made by 12% Adeps Sus domestica, 48% normal feedstuff, 15% sugar, 10% Semen arachidis hypogaeae, 10% egg yolk, 5% salt and 0.03% Fel Sus domestica salt by the quality percentage composition).Feed therebetween (the 8th week), the modeling group is injected 0.25% STZ solution (being dissolved in citric acid solution) by 25mg/Kg BW disposable celiac; The isopyknic citrate buffer of blank group lumbar injection.After 10 weeks, detect each Mus fasting glucose and fasting insulin level, calculate insulin sensitivity index (ISI).
(2) grouping and administration
Take insulin sensitivity index as screening index, screening modeling success rat is 54 in the modeling group, is divided at random the Chinese medicine high dose group (13) of present embodiment, Chinese medicine low dose group (13), rosiglitazone group (14) and the model group (14) of present embodiment.The Chinese medicine high dose group of present embodiment is pressed crude drug amount 10.8g/kg dosage gastric infusion; The Chinese medicine low dose group of present embodiment is pressed crude drug amount 5.4g/kg dosage gastric infusion; The rosiglitazone group is by 0.4mg/kg dosage gastric infusion (the rosiglitazone batch number is 0409002); Blank group and model group gavage the normal saline 10mL/kg of equal volume every day.
(3) concentration of detection Serum Resistin Levels (Resistin), fat element (APN), Serum Leptin Levels (Leptin) and tumor necrosis factor-alpha (TNF-α).
(4) experimental result
The Chinese medicine of table 4 present embodiment is on the impact of rat blood serum Resistin, APN
| Grouping | n | Resistin(ng/mL) | APN(ng/mL) |
| Blank group | 10 | 13.52±3.11 | 4.29±0.60 |
| The Chinese medicine high dose group of present embodiment | 13 | 15.75±2.52 ★★ | 4.22±0.54 ★★ |
| The Chinese medicine low dose group of present embodiment | 13 | 15.52±2.02 ★ | 3.51±0.73 ★ |
| The rosiglitazone group | 14 | 19.54±3.87 | 3.72±0.46 ★★ |
| Model group | 14 | 19.65±3.45 ▲▲ | 2.76±0.71 ▲▲ |
Annotate: 1. compare with the blank group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
Table 4 result shows, compares model group rat blood serum phylaxin (Resistin) level rising (P＜0.01) with the blank group; With model group relatively, star-spangled banner pool core group rat blood serum Resistin level descends, high dose group P＜0.01 wherein, low dose group P＜0.05.Compare model group rat blood serum adiponectin (APN) level decline (P＜0.01) with the blank group; With model group relatively, the Chinese drug-treated group rat blood serum APN level of present embodiment raises, high dose group P＜0.01 wherein, low dose group P＜0.05.
The Chinese medicine of table 5 present embodiment is on the impact of rat blood serum Leptin and TNF-α
| Grouping | n | Leptin(ng/mL) | TNF-a(ng/mL) |
| Blank group | 10 | 2.753±0.541 | 1.657±0.146 |
| The Chinese medicine high dose group of present embodiment | 13 | 3.956±0.543 ★★ | 1.975±0.251 ★★ |
| The Chinese medicine low dose group of present embodiment | 13 | 4.630±0.642 ★★ | 2.452±0.218 ★ |
| The rosiglitazone group | 14 | 5.247±0.764 ★ | 2.154±0.210 ★★ |
| Model group | 14 | 5.876±0.528 ▲▲ | 2.549±0.185 ▲▲ |
Annotate: 1. compare with the blank group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
Table 5 result shows, compares model group serum leptin (Leptin) level rising (P＜0.01) with the blank group; Compare the Chinese medicine high and low dose group rat blood serum Leptin level decline (P＜0.01) of present embodiment with model group.Compare model group rat blood serum tumor necrosis factor-alpha (TNF-α) level rising (P＜0.01) with the blank group; With model group relatively, the Chinese drug-treated group rat blood serum TNF-a level of present embodiment descends, high dose group P＜0.01 wherein, low dose group P＜0.05.
The Chinese medicine of present embodiment can significantly reduce Serum Resistin Levels, leptin, Tumor Necrosis Factor Alpha Levels, and the adiponectin that raises simultaneously can improve the type 2 diabetes mellitus insulin resistant by regulating above Adipocyte Factor level.
Claims (6)
1. Chinese medicine for the treatment of the type 2 diabetes mellitus insulin resistant, the Chinese medicine that it is characterized in that treating the type 2 diabetes mellitus insulin resistant is by weight by 10～20 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 20～40 parts Semen Coicis and 10～20 parts is made.
2. a kind of Chinese medicine for the treatment of the type 2 diabetes mellitus insulin resistant according to claim 1, the Chinese medicine that it is characterized in that treating the type 2 diabetes mellitus insulin resistant is by weight by 10 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 20 parts Semen Coicis and 10 parts is made.
3. a kind of Chinese medicine for the treatment of the type 2 diabetes mellitus insulin resistant according to claim 1, the Chinese medicine that it is characterized in that treating the type 2 diabetes mellitus insulin resistant is by weight by 20 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 40 parts Semen Coicis and 20 parts is made.
4. a kind of Chinese medicine for the treatment of the type 2 diabetes mellitus insulin resistant according to claim 1, the Chinese medicine that it is characterized in that treating the type 2 diabetes mellitus insulin resistant is by weight by 15 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 40 parts Semen Coicis and 20 parts is made.
5. a kind of Chinese medicine for the treatment of the type 2 diabetes mellitus insulin resistant according to claim 1, the Chinese medicine that it is characterized in that treating the type 2 diabetes mellitus insulin resistant is by weight by 20 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 25 parts Semen Coicis and 15 parts is made.
6. a kind of Chinese medicine for the treatment of the type 2 diabetes mellitus insulin resistant according to claim 1, the Chinese medicine that it is characterized in that treating the type 2 diabetes mellitus insulin resistant is by weight by 10 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 30 parts Semen Coicis and 20 parts is made.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110346174 CN102335362B (en) | 2011-11-04 | 2011-11-04 | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110346174 CN102335362B (en) | 2011-11-04 | 2011-11-04 | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102335362A CN102335362A (en) | 2012-02-01 |
| CN102335362B true CN102335362B (en) | 2013-04-10 |
Family
ID=45511462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110346174 Expired - Fee Related CN102335362B (en) | 2011-11-04 | 2011-11-04 | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102335362B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138861B (en) * | 2015-04-05 | 2021-03-12 | 云南云百草实验室有限公司 | Traditional Chinese medicine for treating type II diabetes and preparation method thereof |
| CN112592396B (en) * | 2020-12-14 | 2022-10-21 | 上海交通大学 | Bioactive peptide VDPFSKKDW as well as preparation method and application thereof |
-
2011
- 2011-11-04 CN CN 201110346174 patent/CN102335362B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 中医药治疗2 型糖尿病胰岛素抵抗用药分析;莫娜;《陕西中医》;20090131;第30卷(第1期);89 * |
| 莫娜.中医药治疗2 型糖尿病胰岛素抵抗用药分析.《陕西中医》.2009,第30卷(第1期),89. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102335362A (en) | 2012-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN115364170B (en) | Sugar metabolism regulator and preparation method and application thereof | |
| CN103405655B (en) | Chinese medicine composition of a kind of blood sugar lowering and preparation method thereof | |
| CN103417846B (en) | Chinese medicine composition of a kind of blood sugar lowering and preparation method thereof | |
| CN101856405A (en) | Medicinal composition for treating type II diabetes mellitus and preparation method thereof | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN101317959B (en) | Mastitis plaster for animals preparation and feeding method thereof | |
| CN104815166A (en) | Traditional Chinese medicine composition for treating diabetes as well as preparation and application of traditional Chinese medicine composition | |
| CN100427136C (en) | Medicinal composition for treating fatty liver, its preparation and use | |
| CN102335362B (en) | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes | |
| CN103705796A (en) | Medicinal composition for treating diarrhea, and preparation method thereof | |
| CN103055176B (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN102293928A (en) | Chinese medicinal composition for treating hyperuricemia and urarthritis, and preparation method and application thereof | |
| CN103417694A (en) | Traditional Chinese medicine used for treating diabetes | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN106109951A (en) | Prevent and treat medicine of hyperglycemia, hyperlipidemia, hypertension and preparation method thereof | |
| CN100455317C (en) | Medicament for treating type 2 diabetes | |
| CN105169187B (en) | A kind of composition and its application, preparation method and drug, food containing the composition | |
| CN104740345B (en) | Treat Chinese medicine composition of diabetes and preparation method thereof | |
| CN114617924B (en) | Composition for treating type 2 diabetes | |
| CN108704036A (en) | A kind of Chinese traditional compound medicine and preparation method thereof for treating gout | |
| CN103099865A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN108743885A (en) | A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications | |
| CN107669860A (en) | A kind of Chinese medicine composition and its application with blood sugar reducing function | |
| CN102366481B (en) | Medicine for treating diabetes and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ge Pengling Inventor after: Li Ji Inventor after: Sun Liying Inventor after: Wen Wei Inventor after: Sun Yang Inventor after: Yang Jing Inventor after: Yu Bocheng Inventor before: Ge Pengling Inventor before: Li Ji Inventor before: Sun Liying Inventor before: Wen Wei Inventor before: Sun Yang |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: GE PENGLING LI JI SUN LIYING WEN WEI SUN YANG TO: GE PENGLING LI JI SUN LIYING WEN WEI SUN YANG YANG JING YU BOCHENG |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ge Pengling Inventor after: Li Ji Inventor after: Sun Liying Inventor after: Wen Wei Inventor after: Sun Yang Inventor after: Yang Jing Inventor after: Yu Bocheng Inventor after: Ma Yuxuan Inventor before: Ge Pengling Inventor before: Li Ji Inventor before: Sun Liying Inventor before: Wen Wei Inventor before: Sun Yang Inventor before: Yang Jing Inventor before: Yu Bocheng |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: GE PENGLING LI JI SUN LIYING WEN WEI SUN YANG YANG JING YU BOCHENG TO: GE PENGLING LI JI SUN LIYING WEN WEI SUN YANG YANG JING YU BOCHENG MA YUXUAN |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130410 Termination date: 20181104 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |